Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
8.21
+0.11 (1.30%)
Feb 5, 2026, 4:00 PM EST - Market closed
Bioventus Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 27, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 563.83 | 573.28 | 512.35 | 512.12 | 430.9 | 321.16 | |
Revenue Growth (YoY) | 1.58% | 11.89% | 0.04% | 18.85% | 34.17% | -5.58% |
Cost of Revenue | 181.8 | 185.05 | 184.15 | 181.04 | 128.19 | 87.64 |
Gross Profit | 382.03 | 388.23 | 328.19 | 331.08 | 302.71 | 233.52 |
Selling, General & Admin | 315.11 | 327.09 | 303.88 | 332.13 | 254.25 | 193.08 |
Research & Development | 12.07 | 13.64 | 13.45 | 23.85 | 19.04 | 11.2 |
Operating Expenses | 333.37 | 348.38 | 326.17 | 365.74 | 281.66 | 211.72 |
Operating Income | 48.66 | 39.84 | 2.03 | -34.66 | 21.05 | 21.8 |
Interest Expense | -30.18 | -38.79 | -40.68 | -18.42 | -3.84 | -11.35 |
Interest & Investment Income | - | - | - | 6.4 | 2.73 | 1.6 |
Earnings From Equity Investments | - | - | - | - | -1.87 | -0.47 |
Currency Exchange Gain (Loss) | 1.31 | 1.31 | 0.35 | -0.25 | -0.13 | 0.12 |
Other Non Operating Income (Expenses) | -1.48 | 0.34 | -0.56 | 0.77 | 1.91 | 0.17 |
EBT Excluding Unusual Items | 18.31 | 2.7 | -38.86 | -46.16 | 19.85 | 11.87 |
Merger & Restructuring Charges | 0.05 | 0.05 | -0.84 | -6.78 | -2.49 | -0.56 |
Impairment of Goodwill | - | - | - | -124.7 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -10.29 | -7.04 | 0.51 |
Gain (Loss) on Sale of Assets | -0.37 | -0.29 | -3.58 | - | - | - |
Asset Writedown | -2.46 | -36.36 | -78.62 | - | - | - |
Legal Settlements | -0.13 | -13.8 | 1.5 | - | - | - |
Other Unusual Items | -0.67 | -1.42 | -0.72 | -1.1 | -0.83 | 4.1 |
Pretax Income | 14.73 | -49.13 | -121.11 | -189.03 | 9.49 | 15.91 |
Income Tax Expense | 2.16 | -5.29 | 0.09 | -44.37 | -1.97 | 1.19 |
Earnings From Continuing Operations | 12.57 | -43.83 | -121.2 | -144.65 | 11.45 | 14.72 |
Earnings From Discontinued Operations | - | - | -59.49 | -54.79 | -1.87 | - |
Net Income to Company | 12.57 | -43.83 | -180.69 | -199.44 | 9.59 | 14.72 |
Minority Interest in Earnings | -2.4 | 10.29 | 24.46 | 40.73 | 9.79 | 1.69 |
Net Income | 10.17 | -33.54 | -156.23 | -158.7 | 19.38 | 16.41 |
Preferred Dividends & Other Adjustments | - | - | - | - | 25.98 | - |
Net Income to Common | 10.17 | -33.54 | -156.23 | -158.7 | -6.6 | 16.41 |
Net Income Growth | - | - | - | - | 18.06% | 139.54% |
Shares Outstanding (Basic) | 66 | 65 | 63 | 61 | 45 | 5 |
Shares Outstanding (Diluted) | 68 | 65 | 63 | 61 | 45 | 5 |
Shares Change (YoY) | 6.27% | 3.03% | 2.05% | 35.00% | 828.01% | - |
EPS (Basic) | 0.15 | -0.52 | -2.49 | -2.59 | -0.15 | 3.35 |
EPS (Diluted) | 0.15 | -0.52 | -2.49 | -2.59 | -0.15 | 3.35 |
EPS Growth | - | - | - | - | - | 139.54% |
Free Cash Flow | 53.47 | 37.79 | 7.98 | -25.06 | 9.47 | 55.22 |
Free Cash Flow Per Share | 0.79 | 0.58 | 0.13 | -0.41 | 0.21 | 11.27 |
Gross Margin | 67.76% | 67.72% | 64.06% | 64.65% | 70.25% | 72.71% |
Operating Margin | 8.63% | 6.95% | 0.40% | -6.77% | 4.88% | 6.79% |
Profit Margin | 1.80% | -5.85% | -30.49% | -30.99% | -1.53% | 5.11% |
Free Cash Flow Margin | 9.48% | 6.59% | 1.56% | -4.89% | 2.20% | 17.19% |
EBITDA | 65.97 | 58.98 | 28.85 | -4.68 | 41.52 | 50.44 |
EBITDA Margin | 11.70% | 10.29% | 5.63% | -0.91% | 9.64% | 15.71% |
D&A For EBITDA | 17.3 | 19.14 | 26.82 | 29.97 | 20.47 | 28.64 |
EBIT | 48.66 | 39.84 | 2.03 | -34.66 | 21.05 | 21.8 |
EBIT Margin | 8.63% | 6.95% | 0.40% | -6.77% | 4.88% | 6.79% |
Effective Tax Rate | 14.67% | - | - | - | - | 7.49% |
Advertising Expenses | - | 4.42 | 3.85 | 5.2 | 3.87 | 2.77 |
Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.